Phase 2‐3 Trial: Prevention of the Progression to Moderate and Severe COVID‐19 in SARS‐CoV‐2‐Infected Non‐Hospitalized Adults With Inhaled siRNA‐Based MIR 19
Allergy,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 3, 2025
ABSTRACT
Background
COVID‐19
continues
to
be
a
major
global
health
challenge.
Inhaled
siRNA‐based
MIR
19
has
been
shown
reduce
the
time
clinical
improvement
in
patients
hospitalized
with
moderate
COVID‐19.
Methods
We
conducted
an
open‐label,
randomized,
controlled
multicenter
phase
2b‐3
trial
(NCT05783206)
evaluating
safety
and
efficacy
of
inhaled
siR‐7‐EM/KK‐46
(MIR
19)
(5.55
mg/day)
comparison
standard
care
(control
group)
outpatients
mild
(
N
=
492
for
each
group).
The
primary
endpoint
was
proportion
who
developed
or
severe
by
28th
day
randomization.
Results
Moderate
course
disease
detected
14
(2.85%)
34
(6.91%)
mg)
therapy
groups,
respectively
(the
difference
proportions
−4.107%
[95%
CI:
−7.28%
−1.03%]
p
0.002)).
Adverse
events
(AE)
were
reported
77
(15.65%)
from
group,
while
group
AEs
registered
100
(20.33%)
patients.
No
severe,
treatment‐related
observed
group.
Conclusions
siR‐7‐EM/KK‐46,
SARS‐CoV‐2‐specific
RNAi‐based
drug,
well‐tolerated
significantly
decreased
progression
moderate/severe
Язык: Английский
Vitamin D: A Nutraceutical Supplement at the Crossroad Between Respiratory Infections and COVID-19
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(6), С. 2550 - 2550
Опубликована: Март 12, 2025
Even
though
in
mid-2023
the
World
Health
Organization
declared
end
of
public
health
emergency
international
concern
status
for
COVID-19,
many
areas
uncertainty
about
SARS-CoV-2
infection
pathophysiology
remain.
Although
last
4
years
pharmaceutical
industries
widely
invested
development
effective
antiviral
treatments
and
vaccines,
large
disparities
their
availability
worldwide
still
exist,
thus
fostering
investigation
nutritional
supplements
as
adjuvant
therapeutic
approaches
disease
management,
especially
resource-limited
settings.
During
COVID-19
pandemic,
vitamin
D
has
been
used
an
over-the-counter
solution
to
improve
evolution,
thanks
its
known
immunomodulatory
anti-inflammatory
actions.
Ecological
observational
studies
support
a
relationship
between
hypovitaminosis
negative
outcomes
and,
according
this
evidence,
several
research
groups
investigated
role
supplementation
protecting
from
and/or
improving
evolution.
This
narrative
review
is
intended
offer
insights
into
existing
data
on
D’s
biological
effects
respiratory
infections,
COVID-19.
Furthermore,
it
will
also
brief
overview
complex
interplay
vaccine-elicited
immune
response,
with
special
attention
anti-COVID-19
vaccines.
Язык: Английский
Antivirals in COVID‐19: A Focus on Pediatric Cardiac Patients
Canadian Journal of Infectious Diseases and Medical Microbiology,
Год журнала:
2025,
Номер
2025(1)
Опубликована: Янв. 1, 2025
The
COVID‐19
pandemic
created
an
unprecedented
public
health
crisis,
driven
by
its
rapid
global
spread
and
the
urgent
need
for
worldwide
collaborative
interventions
to
contain
it.
This
urgency
spurred
search
therapeutic
agents
prevent
or
manage
infection.
Among
these,
various
types
of
antivirals
emerged
as
a
prominent
treatment
option,
supported
wealth
observational
studies
randomized
controlled
trials.
results
from
such
conflict,
with
some
concluding
efficacy
others
lack
thereof,
variability
also
occurring
depending
on
severity
in
studied
population.
In
addition,
many
have
been
explored
using
trials—the
gold
standard
evaluating
intervention—to
only
limited
degree,
most
evidence
behind
their
use
concluded
studies.
Thus,
sheer
volume
data
has
made
it
challenging
resolve
inconsistencies
determine
true
efficacy.
Furthermore,
there
is
paucity
literature
regarding
pediatric
population
infected
COVID‐19,
being
extrapolated
done
adult
patients.
As
such,
additional
trials
are
needed
solidify
effectiveness
managing
particularly
underexplored
especially
vulnerable
cardiac
Therefore,
utilizing
trials,
this
narrative
review
evaluates
rationale
antivirals,
summarizes
findings
literature,
concludes
focused
discussion
application
Язык: Английский
Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis
Antiviral Research,
Год журнала:
2024,
Номер
231, С. 106006 - 106006
Опубликована: Сен. 16, 2024
Язык: Английский
Advances and Challenges in Antiviral Development for Respiratory Viruses
Pathogens,
Год журнала:
2024,
Номер
14(1), С. 20 - 20
Опубликована: Дек. 31, 2024
The
development
of
antivirals
for
respiratory
viruses
has
advanced
markedly
in
response
to
the
growing
threat
pathogens
such
as
Influenzavirus
(IAV),
syncytial
virus
(RSV),
and
SARS-CoV-2.
This
article
reviews
advances
challenges
this
field,
highlighting
therapeutic
strategies
that
target
critical
stages
viral
replication
cycle,
including
inhibitors
entry,
replication,
assembly.
In
addition,
innovative
approaches
inhibiting
host
cellular
proteins
reduce
resistance
repurposing
existing
drugs
are
explored,
using
bioinformatics
tools
optimize
identification
antiviral
candidates.
analysis
also
covers
emerging
technologies
nanomedicine
CRISPR
gene
editing,
which
promise
improve
stability
efficacy
treatments.
While
current
offer
valuable
options,
they
face
evolution
need
accessible
treatments
vulnerable
populations.
underscores
importance
continued
innovation
biotechnology
overcome
these
limitations
provide
safe
effective
Combining
traditional
developing
is
essential
order
address
diseases
affect
global
health.
Язык: Английский